Dr Sonneveld on the FDA Approval of Subcutaneous Daratumumab Plus VRd in Myeloma

Описание к видео Dr Sonneveld on the FDA Approval of Subcutaneous Daratumumab Plus VRd in Myeloma

Pieter Sonneveld, MD, PhD, professor, hematology, Erasmus University of Rotterdam, Erasmus Medical Center; chairman, HOVON Multiple Myeloma Working Group, European Myeloma Network, discusses the FDA approval of daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (Darzalex Faspro-VRd; D-VRd) for induction and consolidation in patients with newly diagnosed multiple myeloma who are also candidates for autologous stem cell transplant.

Website: https://www.onclive.com
Twitter:   / onclive  
Facebook:   / onclive  
LinkedIn:   / onclive  

Комментарии

Информация по комментариям в разработке

Похожие видео